10% Owner TCG Crossover Funds Increase Stake in Surrozen with $1.22M Open Market Purchase
SRZN has more than doubled off its 52-week low of $5.9 on light trading volume (0.3× avg).
Summary
TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., along with their general partners, collectively increased their holdings in Surrozen, Inc. through open market purchases totaling over $1.22 million.
Key Events · Ownership and Investor Activity · SRZN
-
Significant Insider Purchase
TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% owners, collectively purchased 48,997 shares of Surrozen, Inc. common stock.
-
Substantial Investment
The open market purchases totaled $1,220,362, executed across six transactions between March 12 and March 16, 2026, at prices ranging from $24.88 to $24.99 per share.
-
Continued Accumulation
This transaction adds to a pattern of insider accumulation, with net insider buys totaling $647,379 in the 90 days prior to this filing, indicating ongoing investor confidence.
Analysis · SRZN · Life Sciences
This Form 4 filing indicates a significant vote of confidence from a major institutional investor. TCG Crossover Funds, identified as 10% owners, acquired over $1.22 million worth of Surrozen common stock through multiple open market transactions between March 12 and March 16, 2026. While 10% owners are financial investors rather than operational insiders, such a substantial purchase suggests a positive outlook on the company's prospects and could be interpreted as a bullish signal for other investors. This purchase contributes to a broader pattern of insider accumulation observed over the last 90 days.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $25.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.6M. The 52-week trading range was $5.90 to $29.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.